BCWORLD PHARM Balance Sheet Health
Financial Health criteria checks 1/6
BCWORLD PHARM has a total shareholder equity of ₩79.9B and total debt of ₩91.2B, which brings its debt-to-equity ratio to 114.2%. Its total assets and total liabilities are ₩184.1B and ₩104.2B respectively. BCWORLD PHARM's EBIT is ₩6.4B making its interest coverage ratio 1.3. It has cash and short-term investments of ₩11.2B.
Key information
114.2%
Debt to equity ratio
₩91.22b
Debt
| Interest coverage ratio | 1.3x |
| Cash | ₩11.17b |
| Equity | ₩79.87b |
| Total liabilities | ₩104.24b |
| Total assets | ₩184.11b |
Recent financial health updates
BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt
Mar 01
Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?
Nov 18
Recent updates
Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) Earnings
Mar 18BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt
Mar 01Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?
Feb 09Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?
Jan 25If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain Today
Jan 11Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?
Dec 26Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?
Nov 18Financial Position Analysis
Short Term Liabilities: A200780's short term assets (₩48.1B) do not cover its short term liabilities (₩92.2B).
Long Term Liabilities: A200780's short term assets (₩48.1B) exceed its long term liabilities (₩12.0B).
Debt to Equity History and Analysis
Debt Level: A200780's net debt to equity ratio (100.2%) is considered high.
Reducing Debt: A200780's debt to equity ratio has increased from 57.2% to 114.2% over the past 5 years.
Debt Coverage: A200780's debt is not well covered by operating cash flow (12%).
Interest Coverage: A200780's interest payments on its debt are not well covered by EBIT (1.3x coverage).